Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.89 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952125 | 0.96 | HCAR2 (1.00) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL1149868 | 0.94 | TSHR (1.00) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL395525 | 0.94 | TSHR (1.00) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL5083071 | 0.82 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL21764920 | 0.82 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL25334427 | 0.78 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL14648769 | 0.78 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL22518545 | 0.78 | HCAR2 (0.64) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL24877853 | 0.78 | HCAR2 (0.64) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL22887837 | 0.77 | TSHR (0.71) | HCAR2KMT2ATSHRGAARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677672-A | Tetrahydrocarbazole-1-formamide derivative and preparation method and application thereof | 厦门大学 | 2023-02-03 | — | — | CN | claimed |
| CN-114853674-A | Production method of medical intermediate 1,4,5, 6-tetrahydro-3-cyclopentapyrazole formonitrile | 浙江安贝特药业有限公司 | 2022-08-05 | — | — | CN | claimed |
| EP-1877365-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2010-11-10 | — | — | EP | claimed |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4612146-A1 | AHR AGONISTS | Eli Lilly and Company (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3873464-B1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005066135-A2 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | HCAR2 3535/4885KMT2A 1678/4885TSHR 3828/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | HCAR2 3979/4885KMT2A 1844/4885TSHR 4027/4885 |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | HCAR2 317/4885KMT2A 1603/4885TSHR 1080/4885 |
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | HCAR2 684/4885KMT2A 2810/4885TSHR 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.